The development of DNA-biochips for rational prescribing of psychologists (Q11681)

From EU Knowledge Graph
Revision as of 07:48, 26 February 2020 by DG Regio (talk | contribs) (‎Created claim: summary (P836): The aim of the project is to develop a new DNA-biochip for a streamlined psychologist for patients with psychiatric illness, thereby bringing benefits not only to the patient but to reducing the costs of health insurance companies. The project will benefit from a safer and more effective psychopharmacy, leading to more successful pharmacotherapy, increasing the comfort of the patient in the form of positive therapy, and reducing the costs of the...)
Jump to navigation Jump to search
Project in Czech Republic financed by DG Regio
Language Label Description Also known as
English
The development of DNA-biochips for rational prescribing of psychologists
Project in Czech Republic financed by DG Regio

    Statements

    0 references
    7,740,698.73 Czech koruna
    0 references
    309,627.94920000003 Euro
    10 January 2020
    0 references
    11,073,961.0 Czech koruna
    0 references
    442,958.44 Euro
    10 January 2020
    0 references
    69.8999999187283 percent
    0 references
    31 October 2020
    0 references
    ESSENCE LINE, s.r.o.
    0 references
    0 references

    50°4'11.50"N, 14°22'51.56"E
    0 references

    50°4'6.46"N, 14°23'8.41"E
    0 references
    15000
    0 references
    15000
    0 references
    Cílem projektu je vyvinout nový DNA-biochip pro racionalizovanou preskripci psychofarmak pro pacienty s psychiatrickým onemocněním a tím přinést prospěch nejen pacientovi, ale snížit náklady zdravotních pojišťoven. Přínosem projektu bude bezpečnější a efektivnější preskripce psychofarmak, což povede k úspěšnější farmakoterapii, zvýší komfort pacienta v podobě pozitivní terapie a sníží náklady na neefektivně aplikovaná psychofarmaka a negativní dopady na pacienta. a. (Czech)
    0 references
    The aim of the project is to develop a new DNA-biochip for a streamlined psychologist for patients with psychiatric illness, thereby bringing benefits not only to the patient but to reducing the costs of health insurance companies. The project will benefit from a safer and more effective psychopharmacy, leading to more successful pharmacotherapy, increasing the comfort of the patient in the form of positive therapy, and reducing the costs of the inefficiently applied psychopharmacy and the negative impacts on the pacemaker. (English)
    0 references

    Identifiers

    CZ.01.1.02/0.0/0.0/17_107/0012433
    0 references